Literature DB >> 6988099

Oncostatic-antibody complexes in chemotherapy.

H F Dullens, R A De Weger.   

Abstract

Cancer-chemotherapeutic agents are not selective in their action against cancer cells. An approach to increasing the efficacy of currently available antitumor drugs is the binding of selected chemotherapeutic agents to antibodies that do posses specific affinity for the tumor cells. In this short review consideration is given to some aspects of induction of antitumor antibodies, techniques for binding of various chemotherapeutic agents to antibodies, immunochemotherapy with oncostatic-antibody complexes and their mode of action, and future prospects of this form of therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6988099     DOI: 10.1007/BF00255454

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  52 in total

1.  Effective antitumour conjugates of alkylating drug and antibody using dextran as the intermediate carrier.

Authors:  G F Rowland
Journal:  Eur J Cancer       Date:  1977-06       Impact factor: 9.162

Review 2.  Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.

Authors:  K E Hellström; I Hellström
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

3.  Augmentation of cytotoxic drug action by antibodies directed at cell surface.

Authors:  R D Rubens; R Dulbecco
Journal:  Nature       Date:  1974-03-01       Impact factor: 49.962

4.  Histoimmunologic specificity of an anti-lymphoid tissue sarcoma gamma-globulin bound to methotrexate.

Authors:  E Calendi; G Costanzi; F Indiveri; G Lotti; C Zini
Journal:  Boll Chim Farm       Date:  1969-01

5.  Factors affecting the noncovalent binding of chlorambucil to rabbit immunoglobulin G.

Authors:  D Blakeslee; J C Kennedy
Journal:  Cancer Res       Date:  1974-04       Impact factor: 12.701

6.  An alkylating agent-globulin conjugate with both alkylating and antibody activity.

Authors:  J H Lindford; G Froese; I Berczi; L G Israels
Journal:  J Natl Cancer Inst       Date:  1974-05       Impact factor: 13.506

7.  The use of macromolecules as carriers of cytotoxic groups (part I) conjugates of nitrogen mustards with proteins, polypeptidyl proteins and polypeptides.

Authors:  M Szekerke; R Wade; M E Whisson
Journal:  Neoplasma       Date:  1972       Impact factor: 2.575

8.  Adsorption to human red blood cells of chlorambucil and other biological alkylating agents.

Authors:  J H Linford; W Hryniuk; L G Israels
Journal:  Biochem Pharmacol       Date:  1969-10       Impact factor: 5.858

9.  An improved method for analyzing survival data from combination chemotherapy experiments.

Authors:  W H Carter; D M Stablein; G L Wampler
Journal:  Cancer Res       Date:  1979-09       Impact factor: 12.701

10.  Chemotherapy of murine ovarian carcinoma by methotrexate-antibody conjugates.

Authors:  S Burstein; R Knapp
Journal:  J Med Chem       Date:  1977-07       Impact factor: 7.446

View more
  2 in total

Review 1.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Daunomycin-arachidonic acid complex as a potential new antitumor agent.

Authors:  T Sasaki; Y Tsukada; H F Deutsch; H Hirai
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.